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ABSTRACT 
Varicella zoster virus (VZV) is an important pathogen after renal transplantation. In the present 
study we examined the prevalence, clinical presentation and outcome of VZV infections in renal 
transplant recipients.  
Charts and medical records of adult renal allotransplant were investigated to discover patients 
with VZV infection.  
From December 1972 until July 2010, 1139 patients received kidney allograft at our institution. 
VZV infection was diagnosed in 40 patients (3.51 %). Twenty eight patients (70%) had 
intensified immunosuppression prior to VZV infection occurrence. Median time of onset was 
2.13 years after transplantation (range 9 days to 19.2 years). Thirty-five patients developed zoster 
during the first post transplant year (median 0.61 years). Four patients developed VZV infection 
more than 12 years after transplantation. Thirty-three patients (82.5%) had dermatomal 
distribution, five (12.5%) disseminated herpes zoster, and 2 patients (5%) who were VZV IgG 
negative before transplantation, developed chickenpox. Immunosuppression was reduced and 
patients received acyclovir. Cutaneous scarring was recorded in 7 cases (17.5%). Two patients 
developed postherpetic neuralgia (PHN), which was in one of them accompanied with scarring 
and skin depigmentation. Five patients (12.5%) experienced relapse of HZ.  
Timely initiation of therapy may prevent development of complications and visceral form of 
disease. Based on our experience with development of chickenpox, we suggest active 
immunization for all seronegative patients before organ transplantation. 
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Introduction 
An individual risk for development of infection after renal transplantation is determined by a 
relationship between the epidemiologic exposure of the individual and the state of 
immunosuppression which determines the individual’s susceptibility to infection (1).  
Varicella zoster virus (VZV) is an important pathogen in organ transplant recipients (2, 3). 
Varicella zoster virus infection causes two clinically different forms of disease. Primary disease 
(varicella or chickenpox) is characterized by vesicular lesions on the trunk, head or extremities. 
Herpes zoster (shringles) is characterized by a painful unilateral vesicular eruption, which may 
rarely be disseminated. 
In the present study we examined the prevalence, clinical presentation and outcome of VZV 
infections in renal transplant recipients.  
 
Patients and method 
Charts and medical records of adult renal allotransplant recipients transplanted between 
December 1972 and July 2010 were investigated to discover patients with VZV infection.  
Patients received triple immunosuppressive regimen (calcineurine inhibitor, antiproliferative drug 
and steroids). Before 2002 we used only azathioprine (AZA) as an antiproliferative drug. Since 
2005 tacrolimus was introduced beside cyclosporine (CyA). From the year 2004 patients with 
more than three mismatches received induction therapy with basiliximab or daclizumab, and until 
that time they were treated with steroid bolus (500mg).  
Age, gender, time on dialysis, time of transplantation, immunosuppressive protocol, viral status 
before transplantation, episodes of acute graft rejection, other viral infections, and graft function 
were recorded. Detailed clinical characteristics of VZV infection were noted (localization, 
dissemination, complications and outcome). 
The diagnosis was made on clinical grounds and/or VZV seroconversion.  
Study was approved by the Ethics Committee of School of medicine, University of Zagreb. 
 
Results 
Patients’ characteristics 
From December 1972 until July 2010, 1139 patients received kidney allograft at our institution. 
VZV infection was diagnosed in 40 patients (3.51 %). There were 27 male patients and 13 female 
patients, with the mean age at diagnosis of 51.8 years (Table 1). Thirty-nine of them received 
renal transplant from deceased donor. Average time on dialysis was 6.8 years. 
 4 
At the time of onset, 36 patients had CyA, MMF and steroids, 2 had tacrolimus, MMF and 
steroids, and two AZA and CyA in therapy. Mean CyA concentration was 157.5 µmol/L (range 
from 85 to 294 µmol/L) and mean dose of MMF was 916 mg/m2 (range from 300 mg/m2 to 1260 
mg/m
2
) at the time of VZV infection. Mycophenolic acid concentration was not determined. Two 
patients receiving tacrolimus had serum concentration of 12.9 and 13.6 ng/mL, and 7 patients had 
CyA C0 >200 µmol/L. Eleven patients (27.5%) received induction therapy with basiliximab or 
daclizumab in their immunosuppressive protocol. Ten patients (25%), 2 of which received 
induction therapy, had acute graft rejection and were treated with 3 to 5 doses of intravenous 
methylprednisolone prior to VZV reactivation. Thus, 28 patients (70%) had enhanced 
immunosuppression prior to VZV infection.  
Six patients (15%) received antiviral treatment before, due to CMV infection. Three patients had 
chronic hepatitis C infection.  
 
Table 1. 
 
Timing of VZV infection 
Median time of onset was 2.13 years after transplantation (range 9 days to 19.2 years). Thirty-five 
patients (85%) developed zoster during the first post transplant year (median 0.61 years). Four 
patients (10%) developed VZV infection long time after transplantation (2 in the year 1988, 1 in 
1992 and 1 in 1998). Two of these patients had received AZA since transplantation, while in two 
patients AZA was replaced with MMF after acute graft rejection, 3.7 and 7.8 years prior to VZV 
infection. None of the patients treated with AZA developed disseminated disease.  
 
Clinical presentation of VZV infection 
Thirty-three patients (82.5%) had dermatomal distribution, five (12.5%) disseminated herpes 
zoster, and 2 patients (5%), who were VZV IgG negative before transplantation, developed 
chickenpox. Severe skin changes were recorded (Figure 1A). Two patients who received organ 
from the same donor developed VZV infection 29 days after transplantation. Donor was VZV 
IgG positive, IgM negative. One recipient was VZV IgG positive and developed disseminated 
vesicular rash (Figure 1B), and another was VZV IgG negative (he developed chickenpox). For 
other patients there was no known exposure to the virus.  
Deterioration of graft function was recorded in one patient, and two had transient elevation of 
liver enzymes.  
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Treatment of VZV infection 
In the treatment of VZV infection, 33 patients (82.5%) received acyclovir orally, 6 patients (15%) 
acyclovir intravenously and one (2.5%) had no antiviral treatment while he failed to visit doctor. 
Antiviral therapy was introduced 0-3 days after vesicular eruption. Seven (17.5%) patients had no 
changes in immunosuppressive treatment (they were treated in local hospitals). MMF was 
reduced in 28, and temporarily switched off in 5 patients.   
 
Complications and outcome 
All patients and grafts survived. Complications occurred in 9 patients (22.5%). Cutaneous 
scarring was recorded in 7 cases (17.5%). Two patients (5%) developed postherpetic neuralgia 
(PHN), which was in one of them accompanied with scarring and skin depigmentation.  
Five patients (12.5%) experienced relapse of HZ. In two of them with 3 or more relapses, 
immunosuppression was changed, and AZA was introduced instead of MMF.   
 
Discussion 
Varicella zoster virus infection is rare but potentially serious complication in renal transplant 
recipients. Lethal outcomes of VZV infection were recorded (2, 4). Our results demonstrated 
relatively low prevalence of VZV infection in renal transplant recipients (3.51%), compared with 
other studies which recorded prevalence of 3 to 10 % (5, 6). Female gender is considered as risk 
factor for developing HZ (5). It is interesting that in our cohort of patients, 67.5 % of patients 
were male. 
The frequency and intensity of VZV infection is associated with the intensity of 
immunosuppression (7, 8). Introduction of mycophenolate mofetil (MMF) in immunosupressive 
protocol improved graft survival (9, 10). However an increased incidence of different viral 
infections was recorded (11-16). According to our results, introduction of MMF in 
immunosuppressive protocol resulted in higher incidence and more severe VZV disease. All our 
patients with disseminated disease were in MMF era. Early therapy with acyclovir orally with 
reduction of MMF dose is a therapy of choice. We believe that dose adjustment and finding an 
upper limit of the therapeutic range of mycophenolic acid (MPA), above which the risk of 
different viral infection is increased, needs to be determined for MMF therapy in the following 
studies (17), at least in patients who received enhanced immunosupression early in the 
posttransplant period. Seventy percent of patients were exposed to intensive immunosuppressive 
treatment before VZV infection, while they received either induction or steroid bolus therapy for 
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treatment of acute rejection, or had high calcineurin inhibitor concentration. This is in line with 
the previous observations that intensive immunosuppression presents risk factor for development 
of VZV infection (1,8). 
Majority of our patients developed VZV infection during the first posttransplant year. Only 4 
patients experienced disease long time after transplantation, thus prolonging the median time of 
onset (2.13 years). Previous studies reported the onset of VZV infection after solid organ 
transplantation to be between 2 and 92 months (3, 5, 18). Switch from AZA to MMF resulted in 
more intensive immunosuppression and subsequently in development of VZV infection in 2 of 
our patients (up to 228 months after transplantation). 
Five cases of disseminated HZ were recorded, what is relatively high proportion in comparison 
with other studies (less than 40 cases described in the literature). Mortality rate of 34 % was 
described in patients with disseminated HZ (2). None of our patients died, probably because of 
the fast recognition and initiation of antiviral therapy.  
We report a low rate of PHN (5 %) in our patients, but relatively high rate of cutaneous scarring 
(17.5 %). Other authors reported PHN up to 42.7 % of solid organ recipients (5, 19). 
High dose acyclovir therapy together with reduction of immunosuppression is a cornerstone of 
VZV infection treatment. Timely initiation of therapy may prevent development of complications 
and visceral form of disease. Based on our experience with development of chickenpox, we 
suggest active immunization for all seronegative patients before organ transplantation. 
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Table 1. Clinical characteristics of the patients. VZV- varicella zoster, MMF- mycophenolate 
mofetil, Aza-azathioprine, CyA-cyclosporine A. 
 
 
 
 
 Number 
Patients 40 
Gender (% male) 67.5  
Age (mean, range) 51.8 (28-69) 
Induction (%) 28.9  
MMF vs. Aza  38 vs. 2 
CyA vs. Tacrolimus 38 vs. 2 
Onset of VZV after transplantation (years; 
mean (range)) 
2.13 
(9 days to 19.2 years) 
Intensified immunosuppression (%) 70  
Localized vs. disseminated 33 vs. 5 
Chickenpox 2 
Treatment (peroral vs. intravenous) 34 vs. 6 
Complications 
- neuropathy 
      -    cutaneous scarring  
 
2 
7 
Relapses (no of patients) 5 
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Figure 1. A – Severe form of localized herpes zoster with central necrosis. B – Disseminated 
herpes zoster. 
 
 
 
